Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$1.59 - $3.16 $23,659 - $47,020
-14,880 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.87 - $5.58 $42,705 - $83,030
14,880 New
14,880 $43,000
Q1 2021

May 17, 2021

SELL
$4.73 - $8.15 $123,840 - $213,383
-26,182 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$4.92 - $30.67 $82,710 - $515,593
16,811 Added 179.39%
26,182 $129,000
Q3 2020

Nov 16, 2020

BUY
$21.66 - $38.86 $202,975 - $364,157
9,371 New
9,371 $225,000
Q2 2020

Aug 14, 2020

SELL
$25.47 - $39.69 $207,860 - $323,910
-8,161 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$31.65 - $45.3 $23,547 - $33,703
744 Added 10.03%
8,161 $284,000
Q4 2019

Feb 14, 2020

BUY
$18.94 - $49.53 $140,477 - $367,364
7,417 New
7,417 $340,000

Others Institutions Holding APRE

About Aprea Therapeutics, Inc.


  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.